Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketZacks Investment Research · 1 day ago
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research · 2 days ago
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?Zacks Investment Research · 2 days ago
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PRNewsWire · 3 days ago
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research · 4 days ago
Can Viking Therapeutics Carve Out a Place in the Obesity Market?Zacks Investment Research · 4 days agoViking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD).
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$1.23 | -$1.10 | Beat |
| Apr 29, 2026 | -$1.01 | -$1.37 | Miss |
| Feb 11, 2026 | -$0.89 | -$1.38 | Miss |
| Oct 22, 2025 | -$0.70 | -$0.81 | Miss |
| Jul 23, 2025 | -$0.44 | -$0.58 | Miss |
| Apr 23, 2025 | -$0.34 | -$0.41 | Miss |